Lev Filimonov

The U.S. Food and Drug Administration has approved Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) as a first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), moving the antibody–drug conjugate from later-line salvage therapy into the initial treatment setting for one of the most aggressive breast cancer subtypes.

Ethan Mollick, a professor at the Wharton School of the University of Pennsylvania and one of the most widely followed academic voices on AI adoption, declared on June 25 that “the chatbot era is over, and agentic systems are coming to tasks beyond engineering,” citing new research using internal OpenAI data from Codex, the company’s autonomous software engineering agent, as evidence of a rapid structural shift in how enterprises deploy AI.

Satya Nadella, chief executive of Microsoft, publicly endorsed venture capitalist Gordon Ritter’s argument that the current decade of automation will reward companies investing in their workforce rather than replacing it — a strategic signal that carries direct implications for how enterprises deploy AI agents and agentic architectures.